Cite
HARVARD Citation
Wen, F. et al. (2020). Patient‐based cost‐effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4‐year prospective randomised phase II study. European journal of cancer care. p. n/a. [Online].